United Kingdom (UK)
Recombinant monoclonal antibody to Glycoprotein. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma 523-11.
UniProt Accession Number of Target Protein: D8VEC1; P19462; O92284
Alternative Name(s) of Target: G; RABV-G
Immunogen: The original antibody was raised by immunizing a BALB/c mouse with several strains of rabies virus.
Specificity: This antibody is specific for two discontinuous epitope regions in antigenic site III.
Application Notes: The original antibody was used for an in vivo neutralization assay. In short mice were treated with this antibody either pre infection and hamsters were treated post infection. With higher doses all mice survived and all hamster receiving the antibody within 24 hours after infection survived (Dietzschold et al., 1990; PMID:2335829, Dietzschold et al., 1992; PMID:1496020, Schumacher et al., 1989; PMID:2760222). The antibody was used for an ELISA on rabies virus glycoprotein. The structure of this antibody was determined using x-ray crystallography. Further this antibody showed the ability to block syncytia formation. The antibody was also used for an in vitro neutralization assay on rabies virus and BHK-21 cells (Yang et al., 2020; PMID:32004500), and on rabies virus and NA cells (Dietzschold et al., 1992; PMID:1496020). This antibody was used for immunofluorescence on Adrab.gp recombinant virus expressing the rabies G protein (Xiang et al., 1996; PMID:8623532).
Antibody first published in:
Schumacher et al. Use of Mouse Anti-Rabies Monoclonal Antibodies in Postexposure Treatment of Rabies J Clin Invest. 1989 Sep;84(3):971-5. PMID:2760222
Note on publication:
The original paper discusses the potential usefulness of a MAb cocktail for the postexposure treatment of human rabies.